Literature DB >> 19773664

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.

Karin Neukam1, Eva Recio, Angela Camacho, Juan Macías, Antonio Rivero, José A Mira, Cristina López, Carmen Almeida, Julián de la Torre, Juan A Pineda.   

Abstract

OBJECTIVES: Although the reproducibility of transient elastometry (TE) in hepatitis C virus (HCV)-monoinfected patients seems to be high, this may not be the case in HIV/HCV-coinfected patients because of different degrees of steatosis and/or inflammation. This study was aimed to determine the interobserver concordance of TE measurements in HIV/HCV-coinfected patients.
METHODS: A total of 188 patients were evaluated in a cross-sectional, prospective study in two hospitals. The interobserver variability of TE results and the rate of unequal classification of significant fibrosis (cutoff value = 7.2 kPa) and cirrhosis (cutoff value = 14.6 kPa) for two observers were evaluated.
RESULTS: The values of liver stiffness (LS) for two observers highly correlated [intraclass correlation index = 0.976; 95% confidence interval (CI): 0.968-0.982]. The kappa indexes for the concordance of patient classification were 0.60 for significant fibrosis and 0.89 for cirrhosis. Using two cutoff points to diagnose or rule out significant fibrosis (LS >or=9 kPa or <6 kPa) yielded a kappa index of 0.96, but 46% of patients were not classified. Covariables that influenced the interobserver agreement were a high interquartile range in the determination (adjusted odd ratio: 0.189; 95% CI: 0.087-0.411; P = 0.001) and elevated levels of triglycerides (adjusted odd ratio: 1.004; 95% CI: 1.000-1.008; P = 0.031).
CONCLUSION: TE measurement is an observer-independent method to evaluate LS in HIV/HCV coinfected patients. The concordance of the classification of mild-to-severe fibrosis is good and for the diagnosis of cirrhosis is excellent. Lower interquartile ranges and triglyceride levels lead to a higher interobserver agreement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19773664     DOI: 10.1097/MEG.0b013e328331a5d0

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Critical comparison of elastography methods to assess chronic liver disease.

Authors:  Mireen Friedrich-Rust; Thierry Poynard; Laurent Castera
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

2.  HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.

Authors:  M Frías; D Rodríguez-Cano; F Cuenca-López; J Macías; A Gordon; B Manzanares-Martín; J A Pineda; Á Camacho; J Torre-Cisneros; J Peña; A Rivero-Juárez; A Rivero
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 3.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

Review 4.  Assessment of liver disease (noninvasive methods).

Authors:  Shruti H Mehta; Geoffrey C Buckle
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

5.  2-dimensional shear wave elastography: Interobserver agreement and factors related to interobserver discrepancy.

Authors:  Kibo Yoon; Woo Kyoung Jeong; Yongsoo Kim; Min Yeong Kim; Tae Yeob Kim; Joo Hyun Sohn
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

6.  Liver stiffness using transient elastography is applicable to canines for hepatic disease models.

Authors:  Antonio Rivero-Juárez; Juan Morgaz; Angela Camacho; Pilar Muñoz-Rascón; Juan Manuel Dominguez; Raquel Sánchez-Céspedes; Julián Torre-Cisneros; Antonio Rivero
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.